Difference between revisions of "Amrubicin (Calsed)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "manufacturer. Instead" to "manufacturer. Instead") |
m |
||
Line 7: | Line 7: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
+ | *[[Non-small cell lung cancer]] | ||
*[[Small cell lung cancer]] | *[[Small cell lung cancer]] | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
==Patient drug information== | ==Patient drug information== | ||
Line 43: | Line 26: | ||
[[Category:Anthracyclines]] | [[Category:Anthracyclines]] | ||
[[Category:Topoisomerase inhibitors]] | [[Category:Topoisomerase inhibitors]] | ||
+ | [[Category:Non-small cell lung cancer medications]] | ||
[[Category:Small cell lung cancer medications]] | [[Category:Small cell lung cancer medications]] | ||
[[Category:PMDA approved drugs]] | [[Category:PMDA approved drugs]] |
Revision as of 16:51, 2 January 2018
General information
Class/mechanism: Synthetic third generation anthracycline and topoisomerase II inhibitor.[1][2]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
Patient drug information
No information available.
Also known as
- Code name: SM-5887
- Generic names: AMR, amrubicin HCI
- Brand name: Calsed